Comparison of anticoagulants for angioplasty show similar outcomes

In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30 to coincide with its presentation at the annual conference of the American College of Cardiology. The study will be published in the April 16 issue of JAMA.

Infusion with abciximab and implantation of an uncoated-stent is a treatment strategy used to reduce major adverse cardiac events (MACE) in patients undergoing angioplasty (percutaneous coronary intervention [PCI]) for ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack). It is uncertain whether there may be similar benefits in replacing abciximab with tirofiban, which could have clinical and economical implications. Drug-releasing stents reduce the need for repeat subsequent procedures to open obstructed blood vessels after elective PCI compared with uncoated stents, however their use in this patient population is discouraged because of conflicting efficacy results and safety concerns.

Marco Valgimigli, M.D., Ph.D., of the Cardiovascular Institute, University of Ferrara, Italy, and colleagues evaluated the effect of high-dose tirofiban and sirolimus-releasing stents compared with abciximab infusion and uncoated-stent implantation in 745 patients with STEMI undergoing PCI. The trial was conducted in Italy, Spain, and Argentina between October 2004 and April 2007.

The researchers found that among the 722 patients (97 percent) who had an interpretable electrocardiogram, at least 50 percent resolution of ST-segment elevation on the electrocardiogram at 90 minutes following PCI occurred in 302 of 361 patients (83.6 percent) and 308 of 361 patients (85.3 percent) in the abciximab and tirofiban groups, respectively. Ischemic and hemorrhagic outcomes were similar in these groups.

At 8 months, the MACE rate was similar among those who received tirofiban (9.9 percent) and those who received abciximab (12.4 percent) but was higher among those who were treated with the uncoated stent (54 patients, 14.5 percent) compared with those who were treated with the sirolimus-releasing stent (29 patients, 7.8 percent). Revascularization (repeat procedure to unblock a blood vessel) was reduced from 10.2 percent with the uncoated stent to 3.2 percent with the sirolimus-releasing stent.

“In summary, our study provides evidence that in a broad population of largely unselected patients undergoing PCI for STEMI, tirofiban therapy is associated with a noninferior resolution from ST-segment elevation at 90 minutes postintervention compared with abciximab, and at 8-month follow-up, MACE are approximately halved by sirolimus-eluting stent implantation compared with uncoated stents,” the authors write.

Source: JAMA and Archives Journals

Related stories:

Statins may prevent miscarriages
Hospital for Special Surgery researchers have found that statins may be able to prevent miscarriages in women who are suffering from pregnancy complications caused by antiphospholipid syndrome (APS), according to a study in mice. In this autoimmune syndrome, the body produces antibodies directed at phospholipids, the main components of cell membranes. This news comes from a study published in the October issue of the Journal of Clinical Investigation that is currently online in advance of print.
Only some Web sites provide patients with reliable information before having an operation
New research published in the Journal of the American College of Surgeons shows unsponsored and professional society Web sites provide significantly higher quality information about common elective surgical procedures compared with commercially sponsored Web sites. In addition, the study authors say that providing patients with technical search terms may increase the likelihood of obtaining reliable surgical information on the Web.
Study finds stroke-prevention surgery safe in growing 80-plus population
New research published in the October issue of Journal of the American College of Surgeons challenges the current opinion that patients in their eighties, who are often deemed "high-risk" due to their advanced age, should not undergo carotid endarterectomy – a stroke-preventing surgical procedure that clears blockages from the neck's carotid arteries.
Nerve stimulation therapy alleviates pain for chronic headache
A novel therapy using a miniature nerve stimulator instead of medication for the treatment of profoundly disabling headache disorders improved the experience of pain by 80-95 percent, according to a new study from the University of California, San Francisco and the National Hospital for Neurology and Neurosurgery in London.
The pepperoni pizza hypothesis
What's the worst that could happen after eating a slice of pepperoni pizza? A little heartburn, for most people.
Proteins in sperm unlock understanding of male infertility says new study
Proteins found in sperm are central to understanding male infertility and could be used to determine new diagnostic methods and fertility treatments according to a paper published by the journal Molecular and Cellular Proteomics (MCP). The article demonstrates how proteomics, a relatively new field focusing on the function of proteins in a cell, can be successfully applied to infertility, helping identify which proteins in sperm cells are dysfunctional.
Study finds barriers to angioplasty for life-threatening heart attacks
Women, the elderly, and patients admitted to the emergency department on weekends are all less likely to receive same-day coronary angioplasty for a life-threatening heart attack in Florida, University of South Florida researchers found. Their study was published this month (Oct. 1) in the American Journal of Cardiology.
End-of-life discussions with physicians may have benefits for patients and caregivers
Terminally ill patients who had end-of-life discussions with physicians were not more likely to experience emotional distress, received less aggressive medical care in their final week of life and had a better quality of life near death, compared to patients who did not have these discussions, according to a study in the October 8 issue of JAMA.

News discussion:

Medicine & Health news